– First Ever Person with Type 1 Diabetes Receives Experimental Encapsulated Human Stem Cell-Derived Beta Cell Replacement Therapy –
New York, NY, October 29, 2014 — JDRF, the leading
research and advocacy organization funding type 1 diabetes (T1D)
research, announced today that JDRF-funded partner, ViaCyte, Inc., a
leading regenerative medicine company, has for the first time ever
implanted a person with type 1 diabetes (T1D) with an experimental
encapsulated cell therapy product candidate, called VC-01TM, which is
being developed for the treatment of T1D. This individual, and others to
follow, is participating in a trial to evaluate the safety and efficacy
of the VC-01 product candidate, a potential replacement source of
insulin-producing cells.
Read the whole story here:
No comments:
Post a Comment
➼ Please leave a comment, help keep me motivated to blog. Your email address will not be published and you will not receive any spam. Any comments with links or spam will not be published so do not waste your time.